SCHEMBL4495584

SCHEMBL4495584

CN(CCN1CCC(OC(=O)N(c2ccccc2-c2ccccc2)N(C(=O)O)c2ccccc2-c2ccccc2)CC1)C(=O)c1cccc(NC(=O)CN2CCCC2)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.45
HPGD P15428 1/20 0.42
CHRM3 P20309 5/20 0.39
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 1/20 0.39
DRD4 P21917 3/20 0.39
ADRB2 P07550 1/20 0.39
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
KDR P35968 1/20 0.38
ATM Q13315 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493982 0.95 CHRM2 (0.45) CHRM2CHRM3ALDH1A1SMN1; SMN2MEN1
SCHEMBL4476500 0.94 CHRM2 (0.45) CHRM2CHRM3ALDH1A1SMN1; SMN2KMT2A
SCHEMBL4495586 0.93 CHRM2 (0.49) CHRM2HPGDCHRM3ALDH1A1SMN1; SMN2
SCHEMBL4483376 0.91 CHRM2 (0.46) CHRM2CHRM3ADRB2
SCHEMBL4466758 0.90 CHRM2 (0.45) CHRM2CHRM3ADRB2
SCHEMBL4485665 0.90 CHRM2 (0.45) CHRM2CHRM3ADRB2
SCHEMBL4489639 0.89 CHRM2 (0.45) CHRM2CHRM3ADRB2
SCHEMBL4490234 0.89 CHRM2 (0.45) CHRM2CHRM3ADRB2
SCHEMBL4471155 0.89 CHRM2 (0.45) CHRM2CHRM3ALDH1A1ADRB2KDM4E
SCHEMBL4481935 0.89 CHRM2 (0.42) CHRM2CHRM3ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed